Isolation of Novel Compounds Involved in RPE Atrophy
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2005 - March 31, 2007
Grant ID
M2005008
Summary
AMD is a disease in which the macula, the central part of the retina of the eye, loses cells that cannot be replaced. This cellular damage is believed to be responsible for the loss of vision. The primary goal of Dr. Vollmer-Snarr’s research efforts is to more completely identify the specific chemical components of the macula that are being damaged and may cause AMD. The chemical composition of the macula strongly suggests that unknown compounds related to the known damaging agent are present. These other components may provide a missing link in our understanding of AMD and other macular diseases. The long-term objective of this project is to provide new insight in order to develop preventative and therapeutic strategies for AMD and other retinal degenerative diseases.
Related Grants
Macular Degeneration Research
Developing a New Treatment for Wet AMD: Targeted Removal of a Disease-Causing Protein
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Celia Bisbach, PhD
Current Organization
University of Wisconsin-Madison
Developing a New Treatment for Wet AMD: Targeted Removal of a Disease-Causing Protein
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Celia Bisbach, PhD
Current Organization
University of Wisconsin-Madison
Macular Degeneration Research
Development of an Oral Treatment for Dry AMD Using Everyday Anti-Inflammatory Drugs
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Marco Bassetto, PhD
Current Organization
University of California, Irvine
Development of an Oral Treatment for Dry AMD Using Everyday Anti-Inflammatory Drugs
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Marco Bassetto, PhD
Current Organization
University of California, Irvine
Macular Degeneration Research
A Novel Implantable Device to Treat Wet Macular Degeneration
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Charles DeBoer, MD, PhD
Current Organization
Stanford University
A Novel Implantable Device to Treat Wet Macular Degeneration
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Charles DeBoer, MD, PhD
Current Organization
Stanford University